Head to Head Comparison: Seagen (NASDAQ:SGEN) versus Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL – Get Rating) and Seagen (NASDAQ:SGEN – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Valuation and Earnings

This table compares Autolus Therapeutics and Seagen’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$7.49 million	67.97	-$148.84 million	($1.39)	-2.12
Seagen	$1.96 billion	18.47	-$610.31 million	($3.49)	-55.39

Autolus Therapeutics has higher earnings, but lower revenue than Seagen. Seagen is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

70.1% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Seagen shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 27.3% of Seagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Autolus Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Seagen has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Autolus Therapeutics and Seagen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	0	0	5	0	3.00
Seagen	0	11	6	0	2.35

Autolus Therapeutics presently has a consensus target price of $8.20, indicating a potential upside of 178.91%. Seagen has a consensus target price of $190.47, indicating a potential downside of 1.46%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than Seagen.

Profitability

This table compares Autolus Therapeutics and Seagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	N/A	-64.42%	-39.68%
Seagen	-31.55%	-23.00%	-17.93%

Summary

Autolus Therapeutics beats Seagen on 8 of the 14 factors compared between the two stocks.

About Autolus Therapeutics

(Get Rating)

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

About Seagen

(Get Rating)

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.